Amy Hacker-Prietz

Amy Hacker-Prietz

Auto-generated profile, based on publicly available information

Amy Hacker-Prietz

Johns Hopkins University School of Medicine, Baltimore, MD

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SMShalini Moningi
Shalini Moningi
SRSiva P. Raman
Siva P. Raman
ADAvani Satish Dholakia
Avani Satish Dholakia
AHAmy Hacker-Prietz
Amy Hacker-Prietz
Tim PawlikTim Pawlik
Tim Pawlik
JHJoseph M. Herman
Joseph M. Herman
328 Background: Stereotactic Body Radiation Therapy (SBRT) is emerging as a possible standard treatment for pancreatic cancer; however, there is limited data to support its efficacy. This study reviews our institution’s experience using SBRT in the treatment of pancreatic cancer (PCA). Methods: Charts of all PCA patients receiving SBRT from January 2010 to June 2013 were retrospectively reviewed. The primary end points were overall survival (OS) and tumor response assessed by RECIST criteria. 95% of the PTV (GTV + 2-3 mm) received a total dose of 20-33 Gy in five fractions (4-6.6 Gy/fraction), with up to 20% heterogeneity allowed. Pre- and post-SBRT chemotherapy regimens included gemcitabine, cisplatin, FOLFIRINOX, 5-FU or paclitaxel. Results: 84 patients received SBRT, with a median follow-up time of 15.3 months. Median age was 66.5 years, 57.1% were male and 65.5% had head tumors. 66 patients received definitive SBRT for locally advanced or borderline resectable PCA, 4 patients were treated with adjuvant SBRT, and 14 received SBRT for treatment of recurrent disease. Median OS from the date of diagnosis for patients receiving definitive radiation was 17.8 mos (95% CI 14.9-20.9).For recurrent patients the median OS from first day of SBRT was 11.8 mos (95%CI 8.3-15.3). In the definitive SBRT group, among patients who were alive and had follow-up scans, the 6 and 12 month local control rate (stable or partial response) based on RECIST criteria was 84.6% and 81.8%, respectively. Five patients underwent surgery following SBRT and all had negative resection margins. Acute toxicity was minimal with most experiencing grade 1 or 2 fatigue and no grade 3/4 acute toxicity. Late grade 3/4 GI toxicity was seen in 5% (4/84) and 1 patient had a grade 5 GI bleed due to direct tumor invasion into the duodenum. Conclusions: Our early results using SBRT in the definitive and recurrent settings show favorable local control, toxicity, and survival when compared to historical outcomes using chemoradiation. Acute and late toxicity was minimal however the optimal dose and fractionation as well as normal tissue dose constraints need to be determined. Integration of SBRT with more aggressive chemotherapy may result in improved outcomes in patients with PCA.

20 January 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SESusannah G. Ellsworth
Susannah G. Ellsworth
SSSabrina C. Sopha
Sabrina C. Sopha
CDCharles G. Drake
Charles G. Drake
JCJian Campian
Jian Campian
SGSusan L. Gearhart
Susan L. Gearhart
JHJoseph M. Herman
Joseph M. Herman
500 Background: Radiation-induced lymphopenia (RIL) is common in patients with rectal cancer and is associated with worse outcomes in rectal cancer and other solid tumors. We investigated whether endorectal brachytherapy (EB) is associated with milder RIL than external radiation treatment (XRT) in patients with rectal cancer and whether EB is associated with altered tumor-infiltrating lymphocyte (TIL) subpopulations. Methods: Records from 11 patients enrolled in a prospective study of EB for T2-3, N0-1 rectal cancer were reviewed; total lymphocyte counts (TLC) at baseline and 2 months after treatment were recorded. EB was given to tumor alone (6.5Gy x 4). XRT was given to the whole pelvis (median dose 50.4Gy). All patients underwent proctectomy after EB/XRT. TLCs from EB patients were compared to 62 rectal cancer patients receiving pelvic XRT + capecitabine. Proctectomy specimens were immunostained for TIL (CD3, CD4, CD8, FoxP3, and CD25) subtypes. Results: Median baseline TLC in EB patients was 1930 vs 1570 cells/uL in XRT patients (p>0.05). Two months after treatment, median TLC was 1550 in EB patients vs 520 in XRT patients (p<0.01). EB patients had higher absolute numbers of CD3, CD4, CD8, and FoxP3+ TILs (Table). Conclusions: EB spares circulating lymphocytes and is associated with increased TIL expression after therapy. Further investigation is needed to determine if there is a causal association between these phenomena and if the increased TIL expression in EB patients is associated with better outcomes in these patients.

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
YCY. Cao
Y. Cao
LCLi Chen
Li Chen
ANAmol Narang
Amol Narang
ZGZ.D. Guss
Z.D. Guss
JMJoseph Moore
Joseph Moore
JHJoseph M. Herman
Joseph M. Herman

1 April 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
ZCZoe L Cosner
Zoe L Cosner
MAMary Armanios
Mary Armanios
AHAmy Hacker-Prietz
Amy Hacker-Prietz
AMAdrian Murphy
Adrian Murphy
ANAmol Narang
Amol Narang

1 April 2013 in Practical Radiation Oncology
Verified
Journal Article
Open access
ADA.S. Dholakia
A.S. Dholakia
JLJ.P. Leal
J.P. Leal
AWA.T. Wild
A.T. Wild
AHA. Hacker-Prietz
A. Hacker-Prietz
MCM. Chaudhry
M. Chaudhry
JHJoseph M. Herman
Joseph M. Herman

1 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LRLauren M. Rosati
Lauren M. Rosati
SMShalini Moningi
Shalini Moningi
AHAmy Hacker-Prietz
Amy Hacker-Prietz
DLDan Laheru
Dan Laheru
LZLei Zheng
Lei Zheng
JHJoseph M. Herman
Joseph M. Herman
454 Background: The purpose of this prospective, non-randomized phase II single-institution study was to evaluate if local control can be achieved with reasonable acute and late GI toxicity using fractionated SBRT in patients with unresectable, recurrent, or residual locally advanced pancreatic cancer (LAPC). Methods: A total of 24 patients with LAPC were enrolled from June 2013 to August 2014. Eligibility required stability after induction chemotherapy or residual disease or local failure after surgery. Induction chemotherapy regimens consisted of: (1) gemcitabine alone (8%); (2) gemcitabine-based regimens (17%); (3) FOLFIRINOX-based regimens (63%); or (4) combination regimens (13%). Chemotherapy was discontinued one week prior to SBRT. Patients received a median cumulative dose of 33 Gy in 5 fractions (5-6.6 Gy/fraction). Patients were permitted to resume chemotherapy one week post-SBRT. Toxicity was assessed using the NCI CTCAE version 4.0. Results: Of the 24 patients, 58% were male and 50% had tumors in the head of the pancreas. Median age at diagnosis was 66.8 years, and median follow-up from the date of diagnosis was 11.9 months (range, 7.4-29.7 months). There have not been any acute or late grade ≥ 2 gastritis, enteritis, fistula, or ulcer toxicities (primary endpoint). Median OS has not yet been reached, median LPFS was 19.3 months (95% CI, 12.3-14.8), median DMFS was 13.6 months (95% CI, 9.2-17.9) and median PFS was 13.6 months (95% CI, 13.5-25.2). Plasma CA 19-9 level was non-significantly reduced after SBRT, displaying a -9.15 average percent change from baseline (median time after SBRT, 1.2 months). FFLP at 1 year was 83.9%. Eight (33%) patients underwent successful surgery following SBRT, with rates of both margin- and node-negative resection being 75%. Conclusions: Chemotherapy followed by fractionated SBRT results in favorable local control and survival with minimal acute and late GI toxicity. A notable proportion of patients initially deemed unresectable underwent successful resection. This study suggests that SBRT can be safely given following more aggressive multiagent chemotherapy in patients with LAPC. Clinical trial information: NCT01781728.